Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
I2O Therapeutics, a US-based developer of orally-administered versions of injectable biological drugs, raised $4m of seed funding on Thursday co-led by Sanofi Ventures and JDRF T1D Fund, respective investment vehicles for pharmaceuticals firm Sanofi and diabetes research finance organisation JDRF. I2O Therapeutics’ platform shields drugs that would ordinarily be destroyed in the digestive tract once swallowed. The company’s lead candidate is an oral version of GLP-1 analogues used to boost hormones in diabetes patients. The funding will support the expansion…
